🔗 Share this article

While the United States proceeds with unprecedented changes to its vaccine recommendations, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and public health researcher who first made her name by expressing skepticism about coronavirus shots throughout the global health crisis and has concentrated on potential fatalities following COVID-19 immunization in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Vaccine Program

Agency leaders planned to reveal major revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would place the US out of alignment with many the international standard with no evidence for public health gain. This reveal has been postponed until the coming year.

Rather than the top vaccines chief, Høeg is listed to address the audience at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this calendar year.

A Shift at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has repeatedly called for ending specific pediatric vaccine recommendations in the US in order to be more similar to Denmark, a nation with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccines – traditionally the purview of Dr. Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

Dr. Høeg has no obvious background in medication creation, regulation or administrative roles, which has been typical for former heads of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former directors of CBER would “grasp regulatory frameworks and the science of medication creation”, said Janet Woodcock. “Objectively, she lacks the type of experience that prior appointees who led the center have had.”

CDER has an enormous workload at the FDA, Woodcock stated.

“Everybody just focuses on the novel medication approvals, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and more, and every single one must be supervised,” Dr. Woodcock noted. “The area you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a significant management element to the job, which oversees in excess of 5,000 personnel. “It’s a enormous administrative position, if you perform it correctly,” she added.

Official Statement and Contentious Programs

In response to questions about Høeg’s fitness for the role and whether this selection represents increased cooperation among regulatory chiefs on vaccines, a press secretary responded that the “questions are based on inaccurate presumptions”.

“Her resume is consistent with the duties of her role,” the official stated, noting the months Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial rapid drug-approval program that allegedly concerned her predecessors. “How are these medications being picked for this fast-track system? Who makes the decisions?” Howard questioned. “There’s a lot of confidentiality happening at the regulatory body right now.”

Overall, he said, “the FDA looks to be trending towards less stringent rules of pharmaceuticals, except for immunizations.”

Public History on Immunizations

Regarding immunizations, Høeg has a more documented, if concerning, track record, critics observe. She authored a analysis using non-validated crowd-sourced reports to estimate the rate of heart inflammation following COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming administration encompassed altering regulations for novel immunizations and ending “optional” immunizations, she said post-election on a online show. At the agency, Høeg has according to sources suggested preventing young men from obtaining Covid vaccinations.

“She is an all-around true believer who starts off with her beliefs and tailors the evidence to accommodate the data in a highly disingenuous, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other skeptics, {like|